What the public didn’t hear about the NIH remdesivir trial

This will not be an article that questions the medical evidence being discussed.  It will focus solely on how the message was communicated to a global audience. I believe that when the results of the NIH-sponsored remdesivir trial – Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases – are … Continue reading What the public didn’t hear about the NIH remdesivir trial